US · Healthcare · Biotechnology
EPS came in at -0.45 against a street estimate of -0.62 — a beat of 27.7%.
Analysts rate Maze Therapeutics, Inc. Common Stock a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $62.55.
| Fund | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 8.25% |
| TRV GP IV, LLC | 8.08% |
| ARCH VENTURE CORP | 7.44% |
| Deep Track Capital, LP | 6.28% |
| HHG PLC | 5.17% |
| Paradigm Biocapital Advisors LP | 4.96% |
| BlackRock Inc | 4.64% |
| VR Adviser, LLC | 2.89% |
| Document | Date |
|---|---|
| Shareholder vote results · Q2 2026 | 2026-06-10 |
| Board / officer change · Q2 2026 | 2026-05-22 |
| Quarterly report · Q1 2026 | 2026-05-12 |
| Results announced · Q2 2026 | 2026-05-12 |
| Proxy statement · Q2 2026 | 2026-04-28 |
| Company announcement · Q2 2026 | 2026-04-22 |
| Annual report FY2025 | 2026-03-25 |
| Quarterly report · Q3 2025 | 2025-11-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Maze Therapeutics, Inc. Common Stock — free to start.
Google PlayApp StoreData updated 2026-08-05.